Skip to content

Updates in Cancer-Associated Thrombosis: Are DOACs Better Than LMWH for Treating Venous Thromboembolism in Cancer Patients

Venous thromboembolism carries a high risk of morbidity and mortality and is the most common type of thromboembolism seen in patients with cancer. Despite this, there are few VTE treatment guidelines targeting this patient group. The program will review recently published guideline updates and new clinical trials regarding direct-acting oral anticoagulants (DOAC) used for treating VTE in patients with cancer. This activity provides an opportunity for pharmacists to apply the most current guidelines and make evidence-based decisions when selecting the most appropriate agent.

Learning Objectives

Upon completion of this activity, the participant will be able to:

  • Describe the epidemiology and pathophysiology of cancer associated thrombosis.
  • List anticoagulant options for the treatment of venous thromboembolism (VTE) in patients with cancer.
  • Explain literature and guideline updates for the treatment of VTE in patients with cancer.
  • Determine appropriate anticoagulation therapy for VTE in patients with cancer.

Presenter

Hanyu (Diana) Dai, PharmD, is a PGY-1 Resident at Baystate Medical Center in Springfield, MA. She earned her PharmD in May 2020 from the Texas Tech University Health and Sciences Center and Bachelor of Science in Microbiology from the University of Texas at Austin. Diana’s primary areas of interest include oncology, infectious disease, and critical care.

Registration Fee: This module is provided free of charge.

Register


Release Date: June 7, 2022
Expiration Date: June 7, 2023
ACPE UAN: 0026-0000-22-132-H01-P | Knowledge
Topic Designator: Disease State Management/Drug Therapy
Contact Hours:
1 (0. 1 CEU)

Accreditation

ACPE logo

Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Massachusetts College of Pharmacy and Health Sciences designates this activity for a total of 1 contact hour (0.1 CEU).

Requirements for Credit

In order to receive credit, the participant must view the entire presentation and complete the pre and post-tests, and evaluation form. Upon completion, participant credit will be reported to CPE Monitor. Transcripts may be printed from CPE Monitor.

Statement of Disclosure

Massachusetts College of Pharmacy and Health Sciences adheres to the ACPE Standards for Integrity and Independence in Continuing Education. It is the policy of MCPHS that the speakers and planning committee members disclose all financial relationships with ineligible companies within the last 24 months, and that relevant conflicts of interest are mitigated. Speakers will disclose any off-label/unapproved use of drugs or devices during their presentation.

Hanyu Dai has no relevant financial relationships with ineligible companies to disclose.

Residency Director Frank Szczerba has no relevant financial relationships with ineligible companies to disclose.

Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies, related to the content of this presentation.

No funding from industry provided for this event. No exhibitors will be present.